SCHEMBL6897607

SCHEMBL6897607

CC(=O)SCCN(CCc1ccc(C)cc1)C(=O)N[C@@H](C)C(=O)N1CCN(C)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
ACACB O00763 1/20 0.33
UGCG Q16739 1/20 0.33
CHRM1 P11229 2/20 0.33
NPC1 O15118 1/20 0.33
MCHR1 Q99705 1/20 0.33
ACE P12821 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6898176 0.91 CYP3A4 (0.39) MEN1KMT2AHSD17B10UGCGCHRM1
SCHEMBL6895628 0.91 CHRM5 (0.39) KMT2AHSD17B10L3MBTL1CHRM1ALDH1A1
SCHEMBL27538415 0.91 HSD17B10 (0.46) HSD17B10CHRM1ACEKDM4EALDH1A1
SCHEMBL6895946 0.91 HSD17B10 (0.46) HSD17B10CHRM1ACEKDM4EALDH1A1
SCHEMBL6891371 0.91 HSD17B10 (0.46) HSD17B10CHRM1ACEKDM4EALDH1A1
SCHEMBL6890745 0.90 MAPT (0.43) KMT2ACHRM1ALDH1A1LMNAGAA
SCHEMBL6898126 0.90 HSD17B10 (0.40) KMT2AHSD17B10CHRM1MCHR1KDM4E
SCHEMBL6898009 0.90 CHRM1 (0.42) MEN1KMT2AHSD17B10UGCGCHRM1
SCHEMBL6893432 0.89 NPC1 (0.34) MEN1KMT2AHSD17B10ACACBCHRM1
SCHEMBL6893749 0.88 SIGMAR1 (0.40) MEN1KMT2AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH MEN1 4882/4885KMT2A 4759/4885HSD17B10 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.